Donepezil Hydrochloride
Product Images NDC 71335-0876

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-0876). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 11 (Donepezil Figur11)

This appears to be a table that shows the change from baseline in SIB score and the LS mean with standard error for patients receiving either 23 mg/day or 10 mg/day of Donepezil hydrochloride. The table also shows the percent improvement and clinical decline over the course of 24 weeks of drug treatment.*

FDA Label Image

Figure 12 (Donepezil Figur12)

The text represents a graph that shows the cumulative percentage of patients taking two different doses of Donepezil hydrochloride (23 mg/day and 10 mg/day) for treating Alzheimer's disease. The graph also displays the SIB (Severe Impairment Battery) change from baseline over time. However, without further context or a visual representation of the graph, it is difficult to determine the significance or interpretation of the information presented.*

FDA Label Image

Figure 13 (Donepezil Figur13)

FDA Label Image

Figure 1 (Donepezil Figure1)

FDA Label Image

Figure 10 (Donepezil Figure10)

The text contains a graph showing the cumulative percentage of patients completing six months of a double-blind treatment with changes from baseline in ADCS-ADL-Severe scores. The text also includes some numbers and characters that do not form coherent words or phrases.*

FDA Label Image

Figure 2 (Donepezil Figure2)

This appears to be a graph or figure showing the cumulative percentage of patients who completed 24 weeks of a double-blind treatment with specified changes from a baseline ADAS-cog score. The graph includes data for a placebo group, a group receiving 5mg/day, and a group receiving 10mg/day. The percentages of patients who completed the study for each group are also included. There is not enough information to determine what specifically the treatment was for or what ADAS-cog scores measure.*

FDA Label Image

Figure 3 (Donepezil Figure3)

The text describes a figure labeled as "Figure 3" that displays a frequency distribution of CIBIC-plus Scores at week 24 based on the percentage of patients who demonstrated marked improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, or marked worsening. It appears to be a graph representing the outcomes of a study or experiment.*

FDA Label Image

Figure 4 (Donepezil Figure4)

This appears to be a section of a scientific report related to drug treatment for patients with ADAS-cog score. It includes a figure depicting the change in ADAS-cog score over time for patients who completed a 15-week study. However, the text appears to be incomplete and contains non-English characters.*

FDA Label Image

Figure 5 (Donepezil Figure5)

FDA Label Image

Figure 6 (Donepezil Figure6)

FDA Label Image

Figure 7 (Donepezil Figure7)

FDA Label Image

Figure 8 (Donepezil Figure8)

The text describes a figure titled "Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in SIB Scores". The figure shows a graph with the percentage of patients on the Y-axis and time on the X-axis, with values ranging from 0 to 100. The graph also displays a line with data points representing the change from baseline in SIB scores. However, there is not enough visible text to understand specific values or to draw any conclusions.*

FDA Label Image

Structure (Donepezil Structure)

FDA Label Image

Label Image (Lbl713350876)

This is a medication label for Donepezil 5mg, a white round tablet used to treat dementia (specifically Alzheimer's disease). The label includes information on storage (room temperature of 20°-25°C or 68°-77°F) and expiration (marked as "EXP MM/YY"). The tablet compares to Aricept 5mg and is produced by Alembic Pharmaceuticals Limited. The label also includes a National Drug Code (NDC) number for identification purposes.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.